JP6611710B2 - 脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法 - Google Patents

脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法 Download PDF

Info

Publication number
JP6611710B2
JP6611710B2 JP2016527092A JP2016527092A JP6611710B2 JP 6611710 B2 JP6611710 B2 JP 6611710B2 JP 2016527092 A JP2016527092 A JP 2016527092A JP 2016527092 A JP2016527092 A JP 2016527092A JP 6611710 B2 JP6611710 B2 JP 6611710B2
Authority
JP
Japan
Prior art keywords
biomarker
tbi
bdnf
level
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016527092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016533499A5 (enExample
JP2016533499A (ja
Inventor
アレン ディー エヴェレット
エイク ジェニファー イー ヴァン
フレッド コーリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2016533499A publication Critical patent/JP2016533499A/ja
Publication of JP2016533499A5 publication Critical patent/JP2016533499A5/ja
Priority to JP2019195925A priority Critical patent/JP6980291B2/ja
Application granted granted Critical
Publication of JP6611710B2 publication Critical patent/JP6611710B2/ja
Priority to JP2021181686A priority patent/JP2022023999A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/825—Metallothioneins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
JP2016527092A 2013-07-17 2014-07-17 脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法 Active JP6611710B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019195925A JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット
JP2021181686A JP2022023999A (ja) 2013-07-17 2021-11-08 脳損傷の予測方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361847213P 2013-07-17 2013-07-17
US61/847,213 2013-07-17
PCT/US2014/046986 WO2015009907A1 (en) 2013-07-17 2014-07-17 A multi-protein biomarker assay for brain injury detection and outcome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019195925A Division JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット

Publications (3)

Publication Number Publication Date
JP2016533499A JP2016533499A (ja) 2016-10-27
JP2016533499A5 JP2016533499A5 (enExample) 2017-08-24
JP6611710B2 true JP6611710B2 (ja) 2019-11-27

Family

ID=52346714

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016527092A Active JP6611710B2 (ja) 2013-07-17 2014-07-17 脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法
JP2019195925A Active JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット
JP2021181686A Pending JP2022023999A (ja) 2013-07-17 2021-11-08 脳損傷の予測方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019195925A Active JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット
JP2021181686A Pending JP2022023999A (ja) 2013-07-17 2021-11-08 脳損傷の予測方法

Country Status (5)

Country Link
US (4) US10534003B2 (enExample)
EP (2) EP3022322A4 (enExample)
JP (3) JP6611710B2 (enExample)
IL (1) IL243393A0 (enExample)
WO (1) WO2015009907A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12172017B2 (en) * 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
WO2013138509A1 (en) * 2012-03-13 2013-09-19 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
EP3022322A4 (en) 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US20180024145A1 (en) 2015-02-05 2018-01-25 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
US10667737B2 (en) 2015-03-23 2020-06-02 International Business Machines Corporation Monitoring a person for indications of a brain injury
FI20155280A7 (fi) * 2015-04-15 2016-10-16 Medicortex Finland Oy Aivovamman prognostisia ja diagnostisia glykaanipohjaisia biomarkkereita
US10244971B2 (en) * 2015-05-12 2019-04-02 International Business Machines Corporation Mouthguard for analysis of biomarkers for traumatic brain injury
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
CA3036714A1 (en) * 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing uch-l1 status in patient samples
US12020820B1 (en) 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en) * 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
EP3610268B1 (en) 2017-04-15 2025-09-24 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
JP7080899B2 (ja) 2017-04-28 2022-06-06 アボット・ラボラトリーズ 同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
WO2018217792A1 (en) 2017-05-23 2018-11-29 Immunarray USA, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
EP3649474A1 (en) 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
US11592452B2 (en) * 2017-07-14 2023-02-28 Mcbi Inc. Disease detection method
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
AU2018324195B2 (en) 2017-09-01 2024-12-12 Venn Biosciences Corporation Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool
WO2019112860A1 (en) * 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
WO2019133717A1 (en) * 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
WO2020006445A1 (en) 2018-06-29 2020-01-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomarkers and treatment methods for traumatic brain injury associated impairments
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020216996B2 (en) * 2019-02-01 2026-05-21 Venn Biosciences Corporation Biomarkers for diagnosing ovarian cancer
WO2020210786A1 (en) 2019-04-12 2020-10-15 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
WO2020223462A1 (en) * 2019-04-30 2020-11-05 University Of Florida Research Foundation, Inc. Biomarker panel for sepsis encephalopathy
KR102464243B1 (ko) * 2020-04-01 2022-11-08 프리시젼바이오 주식회사 외상성 뇌손상 바이오마커 검출용 시분해 형광분석 측방유동 분석장치 및 이를 이용한 외상성 뇌손상 바이오마커 측정방법
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
EP3982123A1 (en) * 2020-10-08 2022-04-13 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Markers and their use in brain injury
KR102189144B1 (ko) * 2020-10-15 2020-12-09 서울대학교병원 만성신장질환 악화 예측 마커 및 이를 이용한 악화 예측 방법
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US20250229086A1 (en) 2022-01-20 2025-07-17 Setpoint Medical Corporation Treatment of inflammatory disorders
FI130340B (en) * 2022-02-22 2023-06-29 Medicortex Finland Oy Procedure for the diagnosis of traumatic brain injury
CN116068191A (zh) * 2022-05-09 2023-05-05 上海众启生物科技有限公司 一种含有icam1蛋白片段的脑梗塞生物标记物及其应用
CA3258179A1 (en) * 2022-06-05 2023-12-14 Sportgait, Inc. HEALTHCARE SYSTEM AND METHODS FOR MANAGING BRAIN INJURIES OR COMMOTIONS
US12649059B2 (en) 2022-08-05 2026-06-09 The Feinstein Institutes For Medical Research Methods for reducing bleeding in hemophilia by vagus nerve stimulation to prime platelets
JP7489723B2 (ja) 2022-10-05 2024-05-24 和哉 松尾 プログラム、情報処理装置、情報処理方法、および学習モデルの生成方法
WO2025188805A1 (en) * 2024-03-04 2025-09-12 University Of Denver Blood based rapid diagnostic system for brain hemorrhage detection and associated methods

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
PT700521E (pt) 1993-05-28 2003-10-31 Baylor College Medicine Metodo e espectrometro de massa para dessorcao e ionizacao de analitos
US5866434A (en) 1994-12-08 1999-02-02 Meso Scale Technology Graphitic nanotubes in luminescence assays
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US6207369B1 (en) 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US6673533B1 (en) 1995-03-10 2004-01-06 Meso Scale Technologies, Llc. Multi-array multi-specific electrochemiluminescence testing
NZ306051A (en) 1995-03-10 1999-11-29 Meso Scale Technologies Llc Testing using electrochemiluminescence
US6319670B1 (en) 1995-05-09 2001-11-20 Meso Scale Technology Llp Methods and apparatus for improved luminescence assays using microparticles
CA2239957A1 (en) 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
EP1068356B8 (en) 1998-04-03 2007-01-03 Adnexus Therapeutics, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6780606B1 (en) 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
AU4025300A (en) 1999-03-24 2000-10-09 Packard Bioscience Company Continuous porous matrix arrays
JP5064625B2 (ja) 1999-10-27 2012-10-31 バイオウルフ テクノロジーズ エルエルスィー パターンを同定するための方法及び機械
WO2002006829A2 (en) 2000-07-18 2002-01-24 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
US20030077590A1 (en) 2000-09-22 2003-04-24 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
WO2002024867A2 (en) 2000-09-22 2002-03-28 University Of Aarhus Novel compositions and methods for lymphoma and leukemia
WO2003031031A1 (en) 2000-11-16 2003-04-17 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US6884591B2 (en) 2001-06-25 2005-04-26 The Cleveland Clinic Foundation Peripheral marker of blood brain barrier permeability
US7144708B2 (en) 2001-06-25 2006-12-05 The Cleveland Clinic Foundation Markers of blood barrier disruption and methods of using same
JP2004534226A (ja) 2001-06-29 2004-11-11 メソ スケイル テクノロジーズ，エルエルシー 発光試験測定用のアッセイプレート、リーダシステム及び方法
US8815577B2 (en) 2001-07-30 2014-08-26 Meso Scale Technologies, Llc Assay electrode having immobilized lipid/protein layers, methods of making the same and methods of using the same for luminescence test measurements
DE60233949D1 (de) 2001-08-20 2009-11-19 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
EP1451348B1 (en) 2001-09-10 2015-08-12 Meso Scale Technologies, LLC Methods, reagents, kits and apparatus for protein function analysis
CA2460114C (en) 2001-09-10 2012-11-06 Meso Scale Technologies, Llc Assay buffer, compositions containing the same, and methods of using the same
US20070098728A1 (en) 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
EP1456668B1 (en) 2001-12-05 2007-05-02 Sense Proteomic Limited Protein arrays for allelic variants and uses thereof
CA2473108A1 (en) * 2002-01-14 2003-07-24 Henry Ford Health System Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
US7036946B1 (en) 2002-09-13 2006-05-02 Rockwell Collins, Inc. LCD backlight with UV light-emitting diodes and planar reactive element
JP2006526140A (ja) * 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
EP1583950B1 (en) 2002-12-26 2017-04-05 Meso Scale Technologies, LLC. Assay cartridges and methods of using the same
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US7981362B2 (en) 2003-11-04 2011-07-19 Meso Scale Technologies, Llc Modular assay plates, reader systems and methods for test measurements
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
WO2005113798A2 (en) 2004-04-15 2005-12-01 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
EP1745149A4 (en) 2004-04-15 2008-08-06 Univ Florida NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
EP1766400B1 (en) 2004-06-03 2009-04-15 Meso Scale Technologies, LLC Methods for conducting whole blood assays
WO2006012351A2 (en) 2004-06-25 2006-02-02 Washington University Markers for brain damage
US20060257943A1 (en) 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
US7884260B2 (en) 2005-06-14 2011-02-08 University Of Chicago Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US20080026485A1 (en) 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
WO2007136617A2 (en) 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
WO2008046509A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Ltbp2 as a biomarker, therapeutic and diagnostic target
AU2007325465B2 (en) 2006-11-28 2013-09-05 Pictor Limited Assay membrane and method of use thereof
WO2008097618A1 (en) 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
EP2015196A1 (en) 2007-06-28 2009-01-14 Siemens Aktiengesellschaft Programmer interface for manufacturing execution system
CA2715248A1 (en) 2008-02-04 2009-08-13 Banyan Biomarkers, Inc. Process to diagnose or treat brain injury
EP2294425B1 (en) 2008-05-23 2013-05-22 The Johns Hopkins University Biomarkers for myocardial ischemia
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20100190656A1 (en) 2008-08-08 2010-07-29 Integrated Diagnostics, Inc. Breast Cancer Specific Markers and Methods of Use
EP3336551B1 (en) 2008-08-11 2023-05-31 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
JP5875514B2 (ja) * 2009-06-19 2016-03-02 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカーアッセイ
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
GB201008541D0 (en) 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
WO2012051519A2 (en) * 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
AU2012211328A1 (en) 2011-01-28 2013-09-19 Cyrex Laboratories, Llc Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
EP2707389B1 (en) * 2011-05-12 2019-10-30 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
WO2012170998A1 (en) 2011-06-10 2012-12-13 Cornell University Immobilized protein system for rapid and enhanced multiplexed diagnostics
WO2013173596A1 (en) 2012-05-16 2013-11-21 Trustees Of Boston University Chronic traumatic encephalopathy in blast-exposed individuals
US20150141528A1 (en) 2013-05-31 2015-05-21 Banyan Biomarkers, Inc. Neural specific s100b for biomarker assays and devices for detection of a neurological condition
EP3022322A4 (en) 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
WO2015066211A1 (en) 2013-10-29 2015-05-07 Banyan Biomarkers, Inc. Uch-l1 isoforms, assays and devices for detection of a neurological condition

Also Published As

Publication number Publication date
IL243393A0 (en) 2016-03-31
JP2020034567A (ja) 2020-03-05
US20230077876A1 (en) 2023-03-16
US20260043814A1 (en) 2026-02-12
EP3022322A4 (en) 2017-05-17
JP2022023999A (ja) 2022-02-08
US10534003B2 (en) 2020-01-14
US12339288B2 (en) 2025-06-24
US11499982B2 (en) 2022-11-15
US20200116739A1 (en) 2020-04-16
US20160178643A1 (en) 2016-06-23
EP3757226A2 (en) 2020-12-30
WO2015009907A1 (en) 2015-01-22
EP3757226A3 (en) 2021-05-05
EP3022322A1 (en) 2016-05-25
JP6980291B2 (ja) 2021-12-15
JP2016533499A (ja) 2016-10-27

Similar Documents

Publication Publication Date Title
JP6980291B2 (ja) 脳損傷の診断／予後判定／評価において有用な組成物及びキット
US20260063646A1 (en) Circulating biomarker levels for diagnosis and risk-stratification of traumatic brain injury
US20250044303A1 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
US12461112B2 (en) Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
US20230238143A1 (en) Multimodality systems and methods for detection, prognosis, and monitoring of neurological injury and disease
JP6071886B2 (ja) 脳損傷のバイオマーカー
US9678086B2 (en) Diagnostic assay for Alzheimer's disease
EP3245520B1 (en) Serum biomarker panels for bipolar disorder
US20140147874A1 (en) Biomarkers of cardiac ischemia
US20250035650A1 (en) Biomarker testing for chronic persistent injury following brain trauma
US20250155455A1 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
WO2025179300A1 (en) Biomarkers, compositions, kits, and methods distinguishing acute geriatric tbi from pre-existing dementia or cognitive impairment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160229

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191029

R150 Certificate of patent or registration of utility model

Ref document number: 6611710

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250